About UCSF Search UCSF UCSF Medical Center

Neil Shah, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
shah_neil

Associate Professor, Department of Medicine (Hematology/Oncology), UCSF
Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center

Edward S. Ageno Distinguished Professorship in Hematology/Oncology, UCSF

nshah@medicine.ucsf.edu

Phone: (415) 353-2421 (medical appts); (415) 514-0269 (academic issues)
Box 1270, UCSF
San Francisco, CA 94143-1270

View on UCSF Profiles


Additional Websites


Education

University of California, Berkeley, BS,1984, Genetics
University of California, Los Angeles, PhD, 1992, Microbiology & Molecular Genetics
University of California, Los Angeles, MD, 1996, Medicine


Professional Experience

  • 1984-1987
    Staff Research Associate, University of California, Los Angeles (UCLA), laboratory of Irvin S.-Y. Chen
  • 1987-1992
    Graduate Student Researcher, UCLA, laboratory of Owen N. Witte
  • 1996-1998
    Internship and Residency, UCLA School of Medicine
  • 1998-2000
    Clinical part of Fellowship in Hematology/Oncology, UCLA School of Medicine
  • 2000-2003
    Postdoctoral Fellow, UCLA, laboratory of Charles L. Sawyers
  • 2003-2004
    Clinical Instructor, Division of Hematology/Oncology, UCLA School of Medicine
  • 2004-2006
    Visiting Assistant Professor, Division of Hematology/Oncology, UCLA School of Medicine
  • 2006-2013
    Assistant Professor, Division of Hematology/Oncology, University of California, San Francisco (UCSF) School of Medicine
  • 2013-present
    Associate Professor, Division of Hematology/Oncology, University of California, San Francisco (UCSF) School of Medicine

Honors & Awards

  • 1989-1991
    National Institutes of Health Predoctoral Award in Tumor Cell Biology
  • 1995
    Alpha Omega Alpha Medical Student Research Prize
  • 1995-2003
    UCLA Specialty Training and Advanced Research (STAR) Award
  • 2001-2004
    Leukemia and Lymphoma Society Career Development Award for Fellows
  • 2003-2005
    NIH K12 Award in Clinical Pharmacology
  • 2004-2007
    Leukemia and Lymphoma Society Career Development Award for Special Fellows
  • 2006-2009
    Doris Duke Charitable Foundation Clinical Scientist Development Award
  • 2009-2014
    Leukemia and Lymphoma Society Scholar in Clinical Research Award

Selected Publications

  1. Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014 Apr 8; 111(14):5319-24.
    View on PubMed
  2. Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014 Apr 10; 123(15):2317-24.
    View on PubMed
  3. Asmussen J, Lasater EA, Tajon C, Oses-Prieto J, Jun YW, Taylor BS, Burlingame A, Craik CS, Shah NP. MEK-Dependent Negative Feedback Underlies BCR-ABL-Mediated Oncogene Addiction. Cancer Discov. 2014 Feb; 4(2):200-15.
    View on PubMed
  4. Politi J, Shah NP. What does a deep molecular response signify? J Clin Oncol. 2014 Feb 10; 32(5):471-4.
    View on PubMed
  5. O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Deangelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Pinilla-Ibarz J, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H. Chronic myelogenous leukemia, version 1.2014. J Natl Compr Canc Netw. 2013 Nov 1; 11(11):1327-40.
    View on PubMed
  6. Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013 Apr 18; 121(16):3165-71.
    View on PubMed
  7. Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2013; 33:313-8.
    View on PubMed
  8. Shah NP. Front-line TKI therapy for chronic-phase CML: the luxury of choice. Oncology (Williston Park). 2012 Oct; 26(10):908, 910, 912.
    View on PubMed
  9. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012 May 10; 485(7397):260-3.
    View on PubMed
  10. Shah NP, Shannon K. Advancing the STATus of MPN pathogenesis. Blood. 2012 Apr 12; 119(15):3374-6.
    View on PubMed
  11. Smith CC, Shah NP. Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia. Am Soc Clin Oncol Educ Book. 2012; 685-9.
    View on PubMed
  12. Shah NP. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia. Clin Adv Hematol Oncol. 2011 Dec; 9(12):925-6.
    View on PubMed
  13. Smith CC, Shah NP. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. Clin Cancer Res. 2011 Nov 1; 17(21):6605-7.
    View on PubMed
  14. Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, Shah NP, Melnick AM, Müschen M. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011 Oct 24; 208(11):2163-74.
    View on PubMed
  15. Smith CC, Shah NP. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol Educ Program. 2011; 2011:121-7.
    View on PubMed
  16. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70.
    View on PubMed
  17. Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010 Feb; 95(2):232-40.
    View on PubMed
  18. Shah NP. Fine-tuning targeted therapy of CML. Blood. 2009 Dec 3; 114(24):4914-5.
    View on PubMed
  19. Paquette RL, Nicoll J, Chalukya M, Gondek L, Jasek M, Sawyers CL, Shah NP, Maciejewski J. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leuk Res. 2010 Jun; 34(6):708-13.
    View on PubMed
  20. Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009 Sep 15; 115(18):4136-47.
    View on PubMed

Go to UCSF Profiles, powered by CTSI